The global Diabetic Neuropathic Pain Drug market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period.
Report Overview
This report provides a deep insight into the global Diabetic Neuropathic Pain Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Diabetic Neuropathic Pain Drug Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Diabetic Neuropathic Pain Drug market in any manner.
Global Diabetic Neuropathic Pain Drug Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
- Astellas Pharma Inc.
- AstraZeneca Plc
- BioDelivery Sciences International, Inc.
- Boehringer Ingelheim GmbH
- Daiichi Sankyo Company, Limited
- Dong-A Socio Group
- Eli Lilly and Company
- Glenmark Pharmaceuticals Ltd.
- Hydra Biosciences, Inc.
- Immune Pharmaceuticals Inc.
- Laboratorios Del Dr. Esteve S.A.
- Lohocla Research Corporation
- Mertiva AB
- Novaremed
- Pharmaleads
- RAPID Pharmaceuticals AG
- Relmada Therapeutics, Inc.
- Sphaera Pharma Pvt. Ltd.
- Theravasc, Inc.
Market Segmentation (by Type)
- AZD-5213
- Clonidine Hydrochloride
- Duloxetine Hydrochloride DR
- E-52862
- Filgrastim
- GERPOOI
- GRC-17536
- Others
Market Segmentation (by Application)
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Diabetic Neuropathic Pain Drug Market
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porters five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
Chapter Outline
Chapter 1 mainly introduces the statistical
scope of the report, market division standards, and market research methods.
Chapter 2 is an executive
summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Diabetic Neuropathic Pain Drug Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Diabetic Neuropathic Pain Drug
1.2 Key Market Segments
1.2.1 Diabetic Neuropathic Pain Drug Segment by Type
1.2.2 Diabetic Neuropathic Pain Drug Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Diabetic Neuropathic Pain Drug Market Overview
2.1 Global Market Overview
2.1.1 Global Diabetic Neuropathic Pain Drug Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Diabetic Neuropathic Pain Drug Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Diabetic Neuropathic Pain Drug Market Competitive Landscape
3.1 Global Diabetic Neuropathic Pain Drug Sales by Manufacturers (2019-2024)
3.2 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Manufacturers (2019-2024)
3.3 Diabetic Neuropathic Pain Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Diabetic Neuropathic Pain Drug Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Diabetic Neuropathic Pain Drug Sales Sites, Area Served, Product Type
3.6 Diabetic Neuropathic Pain Drug Market Competitive Situation and Trends
3.6.1 Diabetic Neuropathic Pain Drug Market Concentration Rate
3.6.2 Global 5 and 10 Largest Diabetic Neuropathic Pain Drug Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Diabetic Neuropathic Pain Drug Industry Chain Analysis
4.1 Diabetic Neuropathic Pain Drug Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Diabetic Neuropathic Pain Drug Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Diabetic Neuropathic Pain Drug Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Diabetic Neuropathic Pain Drug Sales Market Share by Type (2019-2024)
6.3 Global Diabetic Neuropathic Pain Drug Market Size Market Share by Type (2019-2024)
6.4 Global Diabetic Neuropathic Pain Drug Price by Type (2019-2024)
7 Diabetic Neuropathic Pain Drug Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Diabetic Neuropathic Pain Drug Market Sales by Application (2019-2024)
7.3 Global Diabetic Neuropathic Pain Drug Market Size (M USD) by Application (2019-2024)
7.4 Global Diabetic Neuropathic Pain Drug Sales Growth Rate by Application (2019-2024)
8 Diabetic Neuropathic Pain Drug Market Segmentation by Region
8.1 Global Diabetic Neuropathic Pain Drug Sales by Region
8.1.1 Global Diabetic Neuropathic Pain Drug Sales by Region
8.1.2 Global Diabetic Neuropathic Pain Drug Sales Market Share by Region
8.2 North America
8.2.1 North America Diabetic Neuropathic Pain Drug Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Diabetic Neuropathic Pain Drug Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Diabetic Neuropathic Pain Drug Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Diabetic Neuropathic Pain Drug Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Astellas Pharma Inc.
9.1.1 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Basic Information
9.1.2 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product Overview
9.1.3 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product Market Performance
9.1.4 Astellas Pharma Inc. Business Overview
9.1.5 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug SWOT Analysis
9.1.6 Astellas Pharma Inc. Recent Developments
9.2 AstraZeneca Plc
9.2.1 AstraZeneca Plc Diabetic Neuropathic Pain Drug Basic Information
9.2.2 AstraZeneca Plc Diabetic Neuropathic Pain Drug Product Overview
9.2.3 AstraZeneca Plc Diabetic Neuropathic Pain Drug Product Market Performance
9.2.4 AstraZeneca Plc Business Overview
9.2.5 AstraZeneca Plc Diabetic Neuropathic Pain Drug SWOT Analysis
9.2.6 AstraZeneca Plc Recent Developments
9.3 BioDelivery Sciences International, Inc.
9.3.1 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Basic Information
9.3.2 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product Overview
9.3.3 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product Market Performance
9.3.4 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug SWOT Analysis
9.3.5 BioDelivery Sciences International, Inc. Business Overview
9.3.6 BioDelivery Sciences International, Inc. Recent Developments
9.4 Boehringer Ingelheim GmbH
9.4.1 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Basic Information
9.4.2 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product Overview
9.4.3 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product Market Performance
9.4.4 Boehringer Ingelheim GmbH Business Overview
9.4.5 Boehringer Ingelheim GmbH Recent Developments
9.5 Daiichi Sankyo Company, Limited
9.5.1 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Basic Information
9.5.2 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product Overview
9.5.3 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product Market Performance
9.5.4 Daiichi Sankyo Company, Limited Business Overview
9.5.5 Daiichi Sankyo Company, Limited Recent Developments
9.6 Dong-A Socio Group
9.6.1 Dong-A Socio Group Diabetic Neuropathic Pain Drug Basic Information
9.6.2 Dong-A Socio Group Diabetic Neuropathic Pain Drug Product Overview
9.6.3 Dong-A Socio Group Diabetic Neuropathic Pain Drug Product Market Performance
9.6.4 Dong-A Socio Group Business Overview
9.6.5 Dong-A Socio Group Recent Developments
9.7 Eli Lilly and Company
9.7.1 Eli Lilly and Company Diabetic Neuropathic Pain Drug Basic Information
9.7.2 Eli Lilly and Company Diabetic Neuropathic Pain Drug Product Overview
9.7.3 Eli Lilly and Company Diabetic Neuropathic Pain Drug Product Market Performance
9.7.4 Eli Lilly and Company Business Overview
9.7.5 Eli Lilly and Company Recent Developments
9.8 Glenmark Pharmaceuticals Ltd.
9.8.1 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Basic Information
9.8.2 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product Overview
9.8.3 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product Market Performance
9.8.4 Glenmark Pharmaceuticals Ltd. Business Overview
9.8.5 Glenmark Pharmaceuticals Ltd. Recent Developments
9.9 Hydra Biosciences, Inc.
9.9.1 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Basic Information
9.9.2 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product Overview
9.9.3 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product Market Performance
9.9.4 Hydra Biosciences, Inc. Business Overview
9.9.5 Hydra Biosciences, Inc. Recent Developments
9.10 Immune Pharmaceuticals Inc.
9.10.1 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Basic Information
9.10.2 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product Overview
9.10.3 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product Market Performance
9.10.4 Immune Pharmaceuticals Inc. Business Overview
9.10.5 Immune Pharmaceuticals Inc. Recent Developments
9.11 Laboratorios Del Dr. Esteve S.A.
9.11.1 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Basic Information
9.11.2 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product Overview
9.11.3 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product Market Performance
9.11.4 Laboratorios Del Dr. Esteve S.A. Business Overview
9.11.5 Laboratorios Del Dr. Esteve S.A. Recent Developments
9.12 Lohocla Research Corporation
9.12.1 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Basic Information
9.12.2 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product Overview
9.12.3 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product Market Performance
9.12.4 Lohocla Research Corporation Business Overview
9.12.5 Lohocla Research Corporation Recent Developments
9.13 Mertiva AB
9.13.1 Mertiva AB Diabetic Neuropathic Pain Drug Basic Information
9.13.2 Mertiva AB Diabetic Neuropathic Pain Drug Product Overview
9.13.3 Mertiva AB Diabetic Neuropathic Pain Drug Product Market Performance
9.13.4 Mertiva AB Business Overview
9.13.5 Mertiva AB Recent Developments
9.14 Novaremed
9.14.1 Novaremed Diabetic Neuropathic Pain Drug Basic Information
9.14.2 Novaremed Diabetic Neuropathic Pain Drug Product Overview
9.14.3 Novaremed Diabetic Neuropathic Pain Drug Product Market Performance
9.14.4 Novaremed Business Overview
9.14.5 Novaremed Recent Developments
9.15 Pharmaleads
9.15.1 Pharmaleads Diabetic Neuropathic Pain Drug Basic Information
9.15.2 Pharmaleads Diabetic Neuropathic Pain Drug Product Overview
9.15.3 Pharmaleads Diabetic Neuropathic Pain Drug Product Market Performance
9.15.4 Pharmaleads Business Overview
9.15.5 Pharmaleads Recent Developments
9.16 RAPID Pharmaceuticals AG
9.16.1 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Basic Information
9.16.2 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product Overview
9.16.3 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product Market Performance
9.16.4 RAPID Pharmaceuticals AG Business Overview
9.16.5 RAPID Pharmaceuticals AG Recent Developments
9.17 Relmada Therapeutics, Inc.
9.17.1 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Basic Information
9.17.2 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product Overview
9.17.3 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product Market Performance
9.17.4 Relmada Therapeutics, Inc. Business Overview
9.17.5 Relmada Therapeutics, Inc. Recent Developments
9.18 Sphaera Pharma Pvt. Ltd.
9.18.1 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Basic Information
9.18.2 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product Overview
9.18.3 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product Market Performance
9.18.4 Sphaera Pharma Pvt. Ltd. Business Overview
9.18.5 Sphaera Pharma Pvt. Ltd. Recent Developments
9.19 Theravasc, Inc.
9.19.1 Theravasc, Inc. Diabetic Neuropathic Pain Drug Basic Information
9.19.2 Theravasc, Inc. Diabetic Neuropathic Pain Drug Product Overview
9.19.3 Theravasc, Inc. Diabetic Neuropathic Pain Drug Product Market Performance
9.19.4 Theravasc, Inc. Business Overview
9.19.5 Theravasc, Inc. Recent Developments
10 Diabetic Neuropathic Pain Drug Market Forecast by Region
10.1 Global Diabetic Neuropathic Pain Drug Market Size Forecast
10.2 Global Diabetic Neuropathic Pain Drug Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Diabetic Neuropathic Pain Drug Market Size Forecast by Country
10.2.3 Asia Pacific Diabetic Neuropathic Pain Drug Market Size Forecast by Region
10.2.4 South America Diabetic Neuropathic Pain Drug Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Diabetic Neuropathic Pain Drug by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Diabetic Neuropathic Pain Drug Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Diabetic Neuropathic Pain Drug by Type (2025-2030)
11.1.2 Global Diabetic Neuropathic Pain Drug Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Diabetic Neuropathic Pain Drug by Type (2025-2030)
11.2 Global Diabetic Neuropathic Pain Drug Market Forecast by Application (2025-2030)
11.2.1 Global Diabetic Neuropathic Pain Drug Sales (Kilotons) Forecast by Application
11.2.2 Global Diabetic Neuropathic Pain Drug Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Diabetic Neuropathic Pain Drug Market Size Comparison by Region (M USD)
Table 5. Global Diabetic Neuropathic Pain Drug Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Diabetic Neuropathic Pain Drug Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Diabetic Neuropathic Pain Drug Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Diabetic Neuropathic Pain Drug Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diabetic Neuropathic Pain Drug as of 2022)
Table 10. Global Market Diabetic Neuropathic Pain Drug Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Diabetic Neuropathic Pain Drug Sales Sites and Area Served
Table 12. Manufacturers Diabetic Neuropathic Pain Drug Product Type
Table 13. Global Diabetic Neuropathic Pain Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Diabetic Neuropathic Pain Drug
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Diabetic Neuropathic Pain Drug Market Challenges
Table 22. Global Diabetic Neuropathic Pain Drug Sales by Type (Kilotons)
Table 23. Global Diabetic Neuropathic Pain Drug Market Size by Type (M USD)
Table 24. Global Diabetic Neuropathic Pain Drug Sales (Kilotons) by Type (2019-2024)
Table 25. Global Diabetic Neuropathic Pain Drug Sales Market Share by Type (2019-2024)
Table 26. Global Diabetic Neuropathic Pain Drug Market Size (M USD) by Type (2019-2024)
Table 27. Global Diabetic Neuropathic Pain Drug Market Size Share by Type (2019-2024)
Table 28. Global Diabetic Neuropathic Pain Drug Price (USD/Ton) by Type (2019-2024)
Table 29. Global Diabetic Neuropathic Pain Drug Sales (Kilotons) by Application
Table 30. Global Diabetic Neuropathic Pain Drug Market Size by Application
Table 31. Global Diabetic Neuropathic Pain Drug Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Diabetic Neuropathic Pain Drug Sales Market Share by Application (2019-2024)
Table 33. Global Diabetic Neuropathic Pain Drug Sales by Application (2019-2024) & (M USD)
Table 34. Global Diabetic Neuropathic Pain Drug Market Share by Application (2019-2024)
Table 35. Global Diabetic Neuropathic Pain Drug Sales Growth Rate by Application (2019-2024)
Table 36. Global Diabetic Neuropathic Pain Drug Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Diabetic Neuropathic Pain Drug Sales Market Share by Region (2019-2024)
Table 38. North America Diabetic Neuropathic Pain Drug Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Diabetic Neuropathic Pain Drug Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Diabetic Neuropathic Pain Drug Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Diabetic Neuropathic Pain Drug Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Region (2019-2024) & (Kilotons)
Table 43. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Basic Information
Table 44. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product Overview
Table 45. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Astellas Pharma Inc. Business Overview
Table 47. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug SWOT Analysis
Table 48. Astellas Pharma Inc. Recent Developments
Table 49. AstraZeneca Plc Diabetic Neuropathic Pain Drug Basic Information
Table 50. AstraZeneca Plc Diabetic Neuropathic Pain Drug Product Overview
Table 51. AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. AstraZeneca Plc Business Overview
Table 53. AstraZeneca Plc Diabetic Neuropathic Pain Drug SWOT Analysis
Table 54. AstraZeneca Plc Recent Developments
Table 55. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Basic Information
Table 56. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product Overview
Table 57. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug SWOT Analysis
Table 59. BioDelivery Sciences International, Inc. Business Overview
Table 60. BioDelivery Sciences International, Inc. Recent Developments
Table 61. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Basic Information
Table 62. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product Overview
Table 63. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Boehringer Ingelheim GmbH Business Overview
Table 65. Boehringer Ingelheim GmbH Recent Developments
Table 66. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Basic Information
Table 67. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product Overview
Table 68. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Daiichi Sankyo Company, Limited Business Overview
Table 70. Daiichi Sankyo Company, Limited Recent Developments
Table 71. Dong-A Socio Group Diabetic Neuropathic Pain Drug Basic Information
Table 72. Dong-A Socio Group Diabetic Neuropathic Pain Drug Product Overview
Table 73. Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Dong-A Socio Group Business Overview
Table 75. Dong-A Socio Group Recent Developments
Table 76. Eli Lilly and Company Diabetic Neuropathic Pain Drug Basic Information
Table 77. Eli Lilly and Company Diabetic Neuropathic Pain Drug Product Overview
Table 78. Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Eli Lilly and Company Business Overview
Table 80. Eli Lilly and Company Recent Developments
Table 81. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Basic Information
Table 82. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product Overview
Table 83. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Glenmark Pharmaceuticals Ltd. Business Overview
Table 85. Glenmark Pharmaceuticals Ltd. Recent Developments
Table 86. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Basic Information
Table 87. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product Overview
Table 88. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Hydra Biosciences, Inc. Business Overview
Table 90. Hydra Biosciences, Inc. Recent Developments
Table 91. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Basic Information
Table 92. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product Overview
Table 93. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Immune Pharmaceuticals Inc. Business Overview
Table 95. Immune Pharmaceuticals Inc. Recent Developments
Table 96. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Basic Information
Table 97. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product Overview
Table 98. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 99. Laboratorios Del Dr. Esteve S.A. Business Overview
Table 100. Laboratorios Del Dr. Esteve S.A. Recent Developments
Table 101. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Basic Information
Table 102. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product Overview
Table 103. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 104. Lohocla Research Corporation Business Overview
Table 105. Lohocla Research Corporation Recent Developments
Table 106. Mertiva AB Diabetic Neuropathic Pain Drug Basic Information
Table 107. Mertiva AB Diabetic Neuropathic Pain Drug Product Overview
Table 108. Mertiva AB Diabetic Neuropathic Pain Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 109. Mertiva AB Business Overview
Table 110. Mertiva AB Recent Developments
Table 111. Novaremed Diabetic Neuropathic Pain Drug Basic Information
Table 112. Novaremed Diabetic Neuropathic Pain Drug Product Overview
Table 113. Novaremed Diabetic Neuropathic Pain Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 114. Novaremed Business Overview
Table 115. Novaremed Recent Developments
Table 116. Pharmaleads Diabetic Neuropathic Pain Drug Basic Information
Table 117. Pharmaleads Diabetic Neuropathic Pain Drug Product Overview
Table 118. Pharmaleads Diabetic Neuropathic Pain Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 119. Pharmaleads Business Overview
Table 120. Pharmaleads Recent Developments
Table 121. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Basic Information
Table 122. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product Overview
Table 123. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 124. RAPID Pharmaceuticals AG Business Overview
Table 125. RAPID Pharmaceuticals AG Recent Developments
Table 126. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Basic Information
Table 127. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product Overview
Table 128. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 129. Relmada Therapeutics, Inc. Business Overview
Table 130. Relmada Therapeutics, Inc. Recent Developments
Table 131. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Basic Information
Table 132. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product Overview
Table 133. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 134. Sphaera Pharma Pvt. Ltd. Business Overview
Table 135. Sphaera Pharma Pvt. Ltd. Recent Developments
Table 136. Theravasc, Inc. Diabetic Neuropathic Pain Drug Basic Information
Table 137. Theravasc, Inc. Diabetic Neuropathic Pain Drug Product Overview
Table 138. Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 139. Theravasc, Inc. Business Overview
Table 140. Theravasc, Inc. Recent Developments
Table 141. Global Diabetic Neuropathic Pain Drug Sales Forecast by Region (2025-2030) & (Kilotons)
Table 142. Global Diabetic Neuropathic Pain Drug Market Size Forecast by Region (2025-2030) & (M USD)
Table 143. North America Diabetic Neuropathic Pain Drug Sales Forecast by Country (2025-2030) & (Kilotons)
Table 144. North America Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 145. Europe Diabetic Neuropathic Pain Drug Sales Forecast by Country (2025-2030) & (Kilotons)
Table 146. Europe Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 147. Asia Pacific Diabetic Neuropathic Pain Drug Sales Forecast by Region (2025-2030) & (Kilotons)
Table 148. Asia Pacific Diabetic Neuropathic Pain Drug Market Size Forecast by Region (2025-2030) & (M USD)
Table 149. South America Diabetic Neuropathic Pain Drug Sales Forecast by Country (2025-2030) & (Kilotons)
Table 150. South America Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 151. Middle East and Africa Diabetic Neuropathic Pain Drug Consumption Forecast by Country (2025-2030) & (Units)
Table 152. Middle East and Africa Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 153. Global Diabetic Neuropathic Pain Drug Sales Forecast by Type (2025-2030) & (Kilotons)
Table 154. Global Diabetic Neuropathic Pain Drug Market Size Forecast by Type (2025-2030) & (M USD)
Table 155. Global Diabetic Neuropathic Pain Drug Price Forecast by Type (2025-2030) & (USD/Ton)
Table 156. Global Diabetic Neuropathic Pain Drug Sales (Kilotons) Forecast by Application (2025-2030)
Table 157. Global Diabetic Neuropathic Pain Drug Market Size Forecast by Application (2025-2030) & (M USD)
List of Figures
Figure 1. Product Picture of Diabetic Neuropathic Pain Drug
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Diabetic Neuropathic Pain Drug Market Size (M USD), 2019-2030
Figure 5. Global Diabetic Neuropathic Pain Drug Market Size (M USD) (2019-2030)
Figure 6. Global Diabetic Neuropathic Pain Drug Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Diabetic Neuropathic Pain Drug Market Size by Country (M USD)
Figure 11. Diabetic Neuropathic Pain Drug Sales Share by Manufacturers in 2023
Figure 12. Global Diabetic Neuropathic Pain Drug Revenue Share by Manufacturers in 2023
Figure 13. Diabetic Neuropathic Pain Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Diabetic Neuropathic Pain Drug Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Diabetic Neuropathic Pain Drug Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Diabetic Neuropathic Pain Drug Market Share by Type
Figure 18. Sales Market Share of Diabetic Neuropathic Pain Drug by Type (2019-2024)
Figure 19. Sales Market Share of Diabetic Neuropathic Pain Drug by Type in 2023
Figure 20. Market Size Share of Diabetic Neuropathic Pain Drug by Type (2019-2024)
Figure 21. Market Size Market Share of Diabetic Neuropathic Pain Drug by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Diabetic Neuropathic Pain Drug Market Share by Application
Figure 24. Global Diabetic Neuropathic Pain Drug Sales Market Share by Application (2019-2024)
Figure 25. Global Diabetic Neuropathic Pain Drug Sales Market Share by Application in 2023
Figure 26. Global Diabetic Neuropathic Pain Drug Market Share by Application (2019-2024)
Figure 27. Global Diabetic Neuropathic Pain Drug Market Share by Application in 2023
Figure 28. Global Diabetic Neuropathic Pain Drug Sales Growth Rate by Application (2019-2024)
Figure 29. Global Diabetic Neuropathic Pain Drug Sales Market Share by Region (2019-2024)
Figure 30. North America Diabetic Neuropathic Pain Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Diabetic Neuropathic Pain Drug Sales Market Share by Country in 2023
Figure 32. U.S. Diabetic Neuropathic Pain Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Diabetic Neuropathic Pain Drug Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Diabetic Neuropathic Pain Drug Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Diabetic Neuropathic Pain Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Diabetic Neuropathic Pain Drug Sales Market Share by Country in 2023
Figure 37. Germany Diabetic Neuropathic Pain Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Diabetic Neuropathic Pain Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Diabetic Neuropathic Pain Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Diabetic Neuropathic Pain Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Diabetic Neuropathic Pain Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Diabetic Neuropathic Pain Drug Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Diabetic Neuropathic Pain Drug Sales Market Share by Region in 2023
Figure 44. China Diabetic Neuropathic Pain Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Diabetic Neuropathic Pain Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Diabetic Neuropathic Pain Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Diabetic Neuropathic Pain Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Diabetic Neuropathic Pain Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Diabetic Neuropathic Pain Drug Sales and Growth Rate (Kilotons)
Figure 50. South America Diabetic Neuropathic Pain Drug Sales Market Share by Country in 2023
Figure 51. Brazil Diabetic Neuropathic Pain Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Diabetic Neuropathic Pain Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Diabetic Neuropathic Pain Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Diabetic Neuropathic Pain Drug Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Diabetic Neuropathic Pain Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Diabetic Neuropathic Pain Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Diabetic Neuropathic Pain Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Diabetic Neuropathic Pain Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Diabetic Neuropathic Pain Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Diabetic Neuropathic Pain Drug Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Diabetic Neuropathic Pain Drug Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Diabetic Neuropathic Pain Drug Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Diabetic Neuropathic Pain Drug Market Share Forecast by Type (2025-2030)
Figure 65. Global Diabetic Neuropathic Pain Drug Sales Forecast by Application (2025-2030)
Figure 66. Global Diabetic Neuropathic Pain Drug Market Share Forecast by Application (2025-2030)
